NCT06924255View on ClinicalTrials.gov

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Schizophrenia Disorders
Interventions
DRUG

Xanomeline and Trospium Chloride

accelerated titration of Xanomeline and Trospium Chloride

DRUG

Xanomeline and Trospium Chloride

slow titration of Xanomeline and Trospium Chloride

Trial Locations (7)

20877

CenExel CBH, Gaithersburg

33024

CenExel RCA, Hollywood

90504

CenExel CNS - Torrance, Torrance

90706

CenExel CIT LA, Bellflower

92506

CenExel CIT IE, Riverside

92845

CenExel CNS - Garden Grove, Garden Grove

08053

CenExel HRI Marlton, Marlton

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Collaborative Neuroscience Research, LLC

NETWORK